Tuesday, February 10, 2026

The New York Times Changes Its Tune on Marijuana, at Last

By Jim Geraghty

Tuesday, February 10, 2026

 

It’s always a good day when the New York Times editorial board catches up to our Charlie Cooke.

 

Back in November, Charlie wrote a typically insightful and well-thought-out magazine piece lamenting that “marijuana legalization is a good idea with bad consequences”:

 

The United States has some of the greatest and most interesting cities in the world — New York, Chicago, San Francisco — and, over the last five or so years, almost all of them have become unpleasant to walk around in thanks to the ubiquitous smell of weed. Truly, it is everywhere — including, most distressingly, wafting through open-air restaurants and sidewalk cafés. There is a reason that the colloquial name for marijuana is “skunk,” and there is a reason that one tries to avoid skunks: They are not, in any circumstance, nice to be around. . . .

 

Nobody seems to believe that the omnipresent smell of weed is the inevitable consequence of their viewpoint. And they’re right: It’s not. Toleration of the public consumption of marijuana — whether explicit or implicit — is a choice that exists wholly independently of the underlying legal status of the drug. Indeed, when one stops to think about it for a moment, it’s rather peculiar that we have ended up in this position in the first instance. The go-to comparison for cannabis is alcohol. And, in almost every major city in the United States, it is illegal to drink alcohol on the street. How can it possibly be the case that we are more permissive toward a drug that has just been legalized than toward the one that has been a mainstay of our culture (including during Prohibition!) since the beginning of the republic?

 

We could have just put piles of burning tires interspersed throughout the downtowns of major U.S. cities and achieved the same olfactory effect.

 

Charlie also pointed out the absurdity that a culture that has effectively banned tobacco smoking in every public space is now completely fine with smoking marijuana in those same public spaces. A major argument that drove the ban on tobacco smoking in public places was the danger of secondhand smoke. Apparently, both the broader public and most lawmakers have decided that when it comes to marijuana smoking, we’re just not going to worry about that sort of thing.

 

In February 2024 the U.S. Centers for Disease Control and Prevention addressed the issue of secondhand smoke for marijuana:

 

Secondhand cannabis smoke contains many of the same toxic and cancer-causing chemicals found in tobacco smoke and some in higher amounts

 

Secondhand cannabis smoke also contains tetrahydrocannabinol (THC), the compound responsible for most of cannabis’s psychoactive effects (or the “high”). THC can be passed to infants and children through secondhand smoke, and people exposed to secondhand cannabis smoke can experience psychoactive effects, such as feeling high. Recent studies have found strong associations between reports of having someone in the home who uses cannabis (e.g., a parent, relative, or caretaker) and the child having detectable levels of THC.

 

American public life would be better if more leaders of institutions could come out and say, “Hey, I got that decision wrong.” The editors of the New York Times did that Monday:

 

In our editorials, we described marijuana addiction and dependence as “relatively minor problems.” Many advocates went further and claimed that marijuana was a harmless drug that might even bring net health benefits. They also said that legalization might not lead to greater use.

 

It is now clear that many of these predictions were wrong. Legalization has led to much more use. Surveys suggest that about 18 million people in the United States have used marijuana almost daily (or about five times a week) in recent years. That was up from around six million in 2012 and less than one million in 1992. More Americans now use marijuana daily than alcohol.

 

If those 18 million Americans who use marijuana nearly daily were to form their own state, they would be the fifth largest, ranking between New York and Pennsylvania.

 

More than 61 million Americans used marijuana at some point in 2024, including almost 26 percent of high school seniors. Almost 32 percent of first-time marijuana users in the past year were between the ages of twelve and 17. I seem to recall legalization proponents insisting that legalizing marijuana would reduce its use by teens, because “permitting sales in a regulated environment would detract from the illicit market and minimize youth access.”

 

The Times editorial board continues:

 

This wider use has caused a rise in addiction and other problems. Each year, nearly 2.8 million people in the United States suffer from cannabinoid hyperemesis syndrome, which causes severe vomiting and stomach pain. More people have also ended up in hospitals with marijuana-linked paranoia and chronic psychotic disorders.

 

In these discussions, it’s common to find intense disagreement over whether marijuana is addictive or can lead to psychotic disorders, with some people citing their experiences of trying it years ago and never becoming addicted or having bad reactions. But we should not be surprised that different human beings with different body chemistries can experience dramatically different reactions to a psychotropic drug. Research on Hunting Four Horsemen was an eye-opening exercise in learning how much human beings’ bodies and body chemistry can differ; there are groups of human beings who are extremely resistant to anthrax and malaria. The “Baiju sea nomads” of the Philippines, Malaysia, and Indonesia can hold their breath underwater for more than five minutes.

 

One young American might find marijuana addictive, while another does not, and our policies regarding weed ought to be crafted with that in mind.

 

Keep in mind, a decent number of people who use marijuana are getting behind the wheel stoned out of their gourd. A December Washington Post op-ed by Keith Humphreys, a professor of psychiatry at Stanford University, and Beau Kilmer, a co-director of the Rand Drug Policy Research Center, reported:

 

Third, policymakers and advocates in many states did not follow up marijuana legalization with adequate regulations for the industry they created, the higher potency products it produced or the aggressiveness or accuracy with which those products were marketed. How states would detect and deter cannabis-impaired driving is one of many policy problems that did not receive sufficient thought.

 

The consequences are easy to see. A 2024 survey indicated that at least 11.7 million people in the United States had driven under the influence of cannabis in the prior year. That’s not far below the 14.2 million estimated to have driven under the influence of alcohol. Another national study found that in the month before being surveyed, 13 percent of high-school student drivers had driven when they had been using cannabis.

 

One survey published in October found that more than 40 percent of “drivers who died in motor vehicle collisions tested positive for active delta-9-tetrahydrocannabinol (THC) in their system, with average blood levels far exceeding those considered to cause impairment.” Another study from 2022 found “legalization of the recreational use of marijuana was associated with a 6.5 percent increase in injury crash rates and a 2.3 percent increase in fatal crash rates, but the subsequent onset of retail marijuana sales did not elicit additional substantial changes.”

 

Oh, and non-users may not have noticed that dispensaries and weed marketers are apparently rife with nonsense claims about the health benefits from marijuana:

 

Dispensaries operating under the brand of another leading company, Cookies, have promoted “powerful medical benefits,” including “cancer fighting” qualities. A cannabis-infused chocolate bar was, until recently, described as containing properties “beneficial to those suffering” from glaucoma, bacterial infections and Huntington’s disease, a devastating genetic illness.

 

More than a decade after states began legalizing recreational marijuana, businesses are enticing customers with unproven health claims, while largely escaping rigorous oversight. A New York Times review of 20 of the largest brands found that most were selling products with such claims, potentially violating federal and state regulations. And as companies compete, potency has gone up — with some products advertised as having as much as 99 percent THC — and prices have gone down. . . .

 

The Times examined product listings on Weedmaps — a major cannabis e-commerce website — posted for 20 of the country’s top-selling cannabis brands. Of those, 16 had products that potentially violated F.D.A. rules, because the descriptions included health claims.

 

They invoked dozens of conditions, including depression, anxiety, insomnia, inflammation, post-traumatic stress disorder, swelling, migraines, cramping, hypertension, arthritis, muscle spasms, mood swings, asthma, anorexia, P.M.S. and attention deficit hyperactivity disorder. . . .

 

Legal marijuana in the U.S. is now a $47 billion industry. In the state of Massachusetts alone, retailers recorded 46.3 million transactions in 2025.

 

We, the American public, have been on the receiving end of a bait and switch. We were told that mere decriminalization of marijuana, or use in medical prescriptions, was not enough. We were told that legalization and the development of a commercial weed industry would solve states’ budget problems, create jobs, and have no serious harmful effect on children or teens. We were assured that producers, marketers, sellers, and adult users would be responsible, know their limits, and recognize the likely consequences of their actions.

 

The editors would likely disapprove if I directly quoted the great legal mind Vinny Gambini.

 

Instead, we’ve got a massive new industry, with plenty of lobbyists at the federal level and state level. We were assured that this new industry would be appropriately overseen and regulated by the states, but clearly that isn’t happening, and the state governments are now de facto partners in the business, collecting $25 billion in tax revenues. We can all see the harmful effects of people who can’t control their use of it and grow addicted, but . . . those frequent users are now a reliable source of tax revenue for the state.

 

Up until late last year, under federal law, marijuana was a Schedule I drug, “defined as drugs with no currently accepted medical use, a high potential for abuse, and a lack of accepted safety for use of the drug under medical supervision.” In December the Trump administration reclassified it as a Schedule III drug, with “potential for abuse less than the drugs or other substances in Schedules I and II, a currently accepted medical use in treatment in the United States, and a potential for moderate or low physical dependence or high psychological dependence in the event of drug abuse.”

 

As the Washington Post editorial board wrote at the time:

 

Rescheduling would be a tax windfall for marijuana businesses currently unable to claim deductions for operating expenses, such as rent, payroll and marketing. A Schedule III classification allows sellers to write those costs off on their taxes. Anyone interested in helping cannabis corporations make more money — and seeing a lot more advertising for their products — will be thrilled.

 

Moreover, its redesignation would mean regulators at the Food and Drug Administration lack any authority to address the drug’s many negative consequences.

 

The Post argued, “Remove the federal government’s restrictions and let the states sort it out.” Eh, based on what we’ve seen so far, it’s hard to feel all that confident in state governments’ abilities to do all that sorting.

 

Yesterday, the New York Times editorial board concluded the answer was a new federal tax on marijuana. Yes, if you tax something, you usually get less of it, but that doesn’t seem like an adequate response to the scale of the problem, either. It just creates another level of government that gets to collect cash from potheads and white guys with dreadlocks.

 

I like libertarians. I could live very happily in a world or country run by libertarians. But the heart of the libertarian philosophy is the notion that human beings are responsible adults who — and this is the important part — accept the consequences of their own actions and recognize the likely consequences of their actions on others.

 

The problem is that every day we encounter examples of people who don’t. If you get behind the wheel stoned, you are ignoring the likely consequences of your actions on others.

 

One of my favorite pieces of reporting from National Review in recent years was Ryan Mills’s work out in Portland, Ore., where advocates of the decriminalization of hard drugs started living with the consequences of that policy and determined they had made a terrible mistake, with deadly consequences. We must wonder if Americans are belatedly recognizing that the development of a legal weed industry has offered a more widespread but less severe version of that grim outcome — and similar lessons to the ones that Portland learned the hard way.

 

ADDENDUM: In case you missed it yesterday, Noam and Valeria Chomsky have served up some absolute hot garbage excuses for their “deep and sincere and everlasting” friendship with Jeffrey Epstein.

No comments: